-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Lesorb fully degradable sinus drug stent independently developed by Nanjing Ient has completed the enrollment of the "multi-center randomized controlled clinical trial for the treatment of chronic sinusitis"
The registration study was led by the Eye and Ear Nose and Throat Hospital Affiliated to Fudan University, with Professor Yu Hongmeng as the PI, and a number of authoritative clinical trial institutions across the country participated
The Lesorb fully degradable sinus drug stent adopts a unique large mesh design, which effectively reduces the formation of blood scabs, improves the cure rate of chronic sinusitis, and has significant clinical effects
With the continuous increase in the number of patients, the average annual compound growth rate of the market capacity of ENT-related medical devices is also increasing.
In recent years, the incidence of various ENT diseases in China has increased rapidly, and the number of patients with chronic sinusitis has exceeded 120 million
The company's fully degradable sinus drug stent provides effective support for the surgical cavity for 7-14 days to prevent postoperative adhesion; at the same time, it can provide continuous targeted drug delivery for 30 days, inhibit the growth of inflammatory cells, and promote the recovery of normal nasal mucosa
At present, the annual volume of nasal endoscopic surgery in China is about 500,000.
Relevant studies have shown that obstructive sleep apnea (OSA) can cause intermittent hypoxia, hypercapnia and sleep structure disturbance, and can lead to hypertension, coronary heart disease, arrhythmia, cerebrovascular disease, cognitive dysfunction, etc.
The current major solutions for OSA include ventilator positive ventilation and palatopharyngoplasty
At present, domestic ENT devices are mainly concentrated in low-end products, with a relatively low degree of specialization, and have not yet formed the industry leader
At present, the company is about to start a new round of financing, and Xuyi Capital will serve as the financial advisor for this round
(Original abridged)
